Study objective: We estimate the minimum dose and total sedation time of rapidly infused ketamine that achieves 3 to 5 minutes of effective sedation in children undergoing forearm fracture reduction in the emergency department.
INTRODUCTION Background
Ketamine is one of the most common drugs administered to sedate children for painful procedures in the emergency setting. [1] [2] [3] [4] A recent clinical practice guideline for emergency department (ED) ketamine sedation 4 recommended an intravenous loading dose of 1.5 to 2 mg/kg, administered during 30 to 60 seconds for children of all ages. This regimen achieves effective sedation for 5 to 10 minutes but is associated with variably defined recovery to discharge readiness times, ranging from 16 to 110 minutes. [5] [6] [7] [8] The prolonged recovery found in most studies strains ED staffs and work flow. We therefore were interested in determining whether an alternative ketamine administration technique might provide a sufficient period of effective sedation but result in more rapid recovery without an increase in adverse events. We believe that rapid infusion of smaller doses of ketamine achieves clinical effectiveness because it likely results in adequate ketamine concentrations at the site of action in the brain. 9, 10 Because we used a smaller dose, recovery was faster owing to rapid redistribution.
Importance
Rapid infusion of a small ketamine dose is a novel, simple, procedural sedation technique that achieves brief effective sedation with rapid recovery. This study is designed to establish a starting dose of ketamine for this alternate technique for brief procedures.
Goals of This Investigation
The goal of this investigation was to estimate the ED 50 and ED 95 (effective dose in 50% and 95% of patients, respectively) of rapidly infused ketamine for fracture reductions in children.
Editor's Capsule Summary
What is already known on this topic Intravenous ketamine sedation in children traditionally involves doses of 1 to 2 mg/kg administered slowly.
What question this study addressed
Can lower doses of ketamine infused rapidly achieve adequate sedation, and, if so, at what doses?
What this study adds to our knowledge This pilot dose-finding study in 60 children estimated a minimum consistently effective dose of 0.8 mg/kg, with resulting 25-minute median sedation times when only single doses of ketamine were needed.
How this is relevant to clinical practice
These preliminary data suggest that a novel rapid infusion technique can provide brief ketamine sedation in children; however, larger studies are needed to confirm whether adequate sedation is consistently achieved.
MATERIALS AND METHODS Study Design
We used the up-down method to estimate ED 50 and ED 95 . ED 50 is the median effective dose, the dose of rapidly infused ketamine that achieves effective sedation in 50% of children, and ED 95 is the dose of ketamine effective for 95% of children. We studied a cohort of children of different cognitive and developmental stages who were undergoing procedural sedation with ketamine for forearm fracture reduction.
Setting
The study was conducted in the pediatric ED of St. Louis Children's Hospital, a tertiary care pediatric trauma center with an annual ED census of 54,000 visits per year. Washington University's institutional review board approved the study.
Selection of Participants
A convenience sample of healthy children who were American Society of Anesthesiology physical status I and II, were between aged 2 and 17 years, and required sedation for forearm fracture reduction in the ED were enrolled. Patients were identified from the ED electronic patient tracking board as study candidates after the treating physician had decided that ketamine sedation was indicated. Patients were enrolled in the study when the principal investigator (S.S.C.) was available. The principal investigator obtained signed consent from the patients' parents and assent from cognitively capable children who were older than 5 years. Exclusion criteria included temperature greater than or equal to 38 C (100.4 F) because of upper respiratory infection, obesity defined as body mass index greater than 2 SD for age and sex or undernourishment defined as body mass index less than 2 SD for age and sex; psychiatric diagnosis with the patient currently under the care of a psychiatrist or receiving psychiatric medication, with the exception of patients with attention deficit hyperactivity disorder, who were not excluded; previous adverse reactions with ketamine sedation; multiple fractures requiring reduction; non-Englishspeaking parents; foster care; or previous participation in the current research project.
Methods of Measurement
The principal investigator performed all sedations to ensure quality and adherence to the research protocol. On-call orthopedic residents who were in their second or higher year of residency training at Washington University in St. Louis performed the fracture reductions. Children received opioid analgesia at the discretion of the treating physician at or after triage for preprocedural fracture-related pain. No patient was pretreated or concurrently treated with midazolam or other sedative. All children were monitored by direct observation and standard cardiorespiratory monitoring (Phillips IntelliVue MP30 patient monitor, Andover, MA), including continuous monitoring of pulse rate with ECG, respiratory rate, oxygen saturation with pulse oximetry, and end-tidal CO 2 by nasal capnography (Phillips EGM gas monitor). Supplemental oxygen was not administered except in response to an adverse clinical event. Blood pressure was recorded before and 2 minutes after administration of ketamine and then every 5 minutes. Parental presence throughout the sedation, procedure, and recovery was permitted. The standard St. Louis Children's Hospital procedural sedation record was used to document presedation evaluation, patient monitoring during the procedural sedation, and postsedation recovery. Adverse events or effects as defined in consensus-based recommendations 11 were documented for each patient. Ondansetron was administered in response to nausea or vomiting but not as prophylaxis.
We targeted a sedation score of less than or equal to 2 on the Children's Hospital of Wisconsin Sedation Scale 12 (Table E1 , available online at http://www.annemergmed. com) for intended depth of sedation. The modified Aldrete score (Table E2 , available online at http://www. annemergmed.com) was used to assess recovery. 13 An
Aldrete score of 10 and a Children's Hospital of Wisconsin sedation score of 5 indicated sufficient recovery (readiness) for hospital discharge. After completion of the fracture reduction, the principal investigator assessed the patient at 5-minute intervals to determine the degree of recovery from sedation. A patient was considered fully awake (Aldrete criteria for consciousness) if he or she was able to sit unassisted, hold and eat a Popsicle, and respond appropriately to simple questions, and had minimal or no dizziness (in patients who could express dizziness). Total sedation time included both the procedure and postsedation recovery periods and was defined as beginning with administration of the first dose of ketamine and ending when the patient achieved an Aldrete score of 10 and a sedation score of 5. Procedure time was defined as starting with the initial fracture reduction attempt (1 minute after ketamine infusion) and ending with completion of the fracture reduction. A nurse or a medic trained in procedural sedation monitored all patients independently to document vital signs and adverse events. At discharge, the principal investigator asked patients (or their parents for younger children) if they had experienced any itchiness, rash, double vision, abdominal pain, dizziness, or shivering during or after recovery. He also inquired whether the patient had any unpleasant recall of the procedure and patient and family preference to receive similar sedation in the future, should the need arise. The principal investigator called the family within 2 weeks to inquire about any adverse events after discharge, including whether the patient had had dry mouth, dizziness, balance problems, nausea, headache, vomiting, nightmares or pleasant dreams, hallucinations, excessive sleepiness or difficulty falling asleep, pain after discharge, or any other symptoms, and whether the patient had missed school or the caretaker had missed work to care for the patient. We compared the frequency of adverse events in our study with a meta-analysis that reported the type and frequency of adverse events associated with ketamine sedations in children. 14, 15 We used the up-down method of Dixon 16 to estimate the ED 50 and ED 95 for each age group. According to pharmacodynamic studies 17 and our experience, we used the following starting ketamine doses for the initial patient in each patient cohort: 1.0 mg/kg for the first patient aged 2 to 5 years, 0.6 mg/kg for the first patient aged 6 to 11 years, and 0.5 mg/kg for the first patient aged 12 to 17 years. Within each cohort, the subsequent patient's initial ketamine dose was determined by the effectiveness of the previous patient's initial ketamine dose. Effectiveness of each patient's initial dose was assessed by 3 independent reviewers, as detailed below. If the previous patient's initial ketamine dose was deemed ineffective, the subsequent patient's initial ketamine dose was incremented upward by 0.1 mg/kg. Likewise, if the previous patient's initial ketamine dose was deemed effective, the subsequent patient's initial ketamine dose was incremented downward by 0.1 mg/kg. This process was continued serially for 20 participants within each of the age groups. This up-down incremental series of doses with associated success or failure brackets the median effective dose (ED 50 ) for that population. We used racemic ketamine hydrochloride for this study (Ketalar 10 mg/mL; JHP Pharmaceuticals LLC).
Ketamine followed by a 5-mL normal saline solution flush was infused intravenously in less than or equal to 5 seconds. One minute later, the fracture was manipulated.
We assessed the depth of sedation at this point with the Children's Hospital of Wisconsin Sedation Scale. 12 A priori, we defined the criteria for effective sedation ( Figure E1 , available online at http://www.annemergmed. com). At any time during the procedure, if the participant verbalized significant pain, showed significant distress, resisted the procedure, or required restraint, additional ketamine was administered to complete the procedure. The amount of ketamine for the additional dose was determined by the sedation provider according to the response to the previous dose and was administered by rapid infusion technique. Only the first ketamine dose and initial reduction attempt were considered in assessing the dose's sedation efficacy. A reduction attempt was defined as contiguous manipulations by the orthopedic surgeon to realign the fracture, with confirmation by bedside fluoroscopy.
All reductions were video recorded by the principal investigator onto DVDs from presedation state to complete recovery. Discrete and waveform form data from the patient's bedside monitor were synchronously video recorded in a picture-in-picture format with the view of the patient throughout the sedation, procedure, and recovery. Data elements included pulse rate, blood pressure, respiratory rate (by impedance plethysmography and by end-tidal capnography), O 2 saturation, ETCO 2 , and capnography. This recording and the monitoring nurse's or medic's handwritten procedural sedation record, along with the principal investigator's direct observations, were available to assess for cardiopulmonary depression or other adverse events.
Effectiveness of sedation from the initial ketamine dose was determined after the patient's discharge by soliciting the opinions of 3 expert reviewers who each independently reviewed a 5-minute segment of each patient's audio-video recording. The segment began with administration of the predetermined initial ketamine dose and included the first fracture reduction attempt. The principal investigator transmitted this 5-minute audio-video segment to a secure Web-based Dropbox and notified the 3 reviewers (C.R.S., J.D.M., and R.M.K.) by e-mail of each new recording.
These reviewers then independently accessed the Dropbox to view the recording to assess the sedation effectiveness of each patient's initial ketamine dose, using the criteria for effective sedation ( Figure E1 , available online at http://www.annemergmed.com). All reviewers were blinded to the dose administered and did not participate in the fracture reduction or sedation. Their independent assessments were transmitted by e-mail to the principal investigator. The initial ketamine dose was deemed effective if at least 2 reviewers agreed that the sedation was effective. If only 2 reviewers were available to review a video and agreed on the effectiveness, it was considered 100% agreement.
We created an independent data and safety monitoring board composed of a pediatric anesthesiologist, pediatric intensivist, and a pediatric hospitalist, all of whom were not study investigators, to review any major adverse events. A data and safety monitoring plan was established before the start of the study. Study stopping criteria included laryngospasm, apnea, or respiratory depression requiring positive-pressure ventilation in 2 or more patients.
Outcome Measures
The primary outcome for this study was to find the ED 50 and ED 95 of rapidly infused ketamine for each age group. The secondary outcomes were total sedation time, frequency of adverse events in the ED, and patient or parent satisfaction.
Primary Data Analysis
A sample size of 20 per group is based on previous studies that used the up-down method, in which typical samples of 20 to 40 were used. 18 The logistic regression model was used to estimate ED 50 and ED 95 , and dose response curves based on dose were analyzed. 19, 20 The 95% confidence intervals for the ED 50 and ED 95 were calculated with the profile penalized likelihood approach. All analyses were conducted with SAS (SAS Institute, Inc., Cary, NC) at the 2-sided 5% significance level. k Statistics were calculated for consensus decisions and individual graders to reflect agreement. 21 
RESULTS

Characteristics of Study Subjects
Sixty-two patients were enrolled between May 2012 and September 2013. Two patients in the group aged 12 to 17 years were excluded from analysis after enrollment because of errors in the initial dose of ketamine administered. Sixtyfive percent of fractures were displaced (full cortical disruption); in 25% of cases, the fragments were overriding. Patient characteristics are detailed in Table 1 .
Main Results
The calculated estimate of the ED 95 for the group aged 2 to 5 years was 0.7 mg/kg. However, review of the data suggested an empiric estimate of 0.8 mg/kg. All patients who received the empirically derived ED 95 in the group aged 2 to 5 years and the estimated ED 95 in the groups aged 6 to 11 and 12 to 17 years had effective sedation with the first dose of ketamine. The median total sedation time for the 3 age groups, respectively, was 25, 22.5, and 25 minutes when only 1 dose of ketamine was administered and somewhat longer if additional doses of ketamine were needed (Table 2 ). For each patient enrolled, the first dose of ketamine, Wisconsin Sedation Scale score at one minute, sedation effectiveness, and total None of the patients had a major adverse event, including apnea, laryngospasm, or oxygen desaturation requiring intervention. One patient (5%) in each of the 3 age groups vomited before discharge. Of the 56 patients reached by telephone for follow-up, postdischarge vomiting occurred in 32% in the group aged 2 to 5 years and in 17% and 16% in the groups aged 6 to 11 and 12 to 17 years, respectively. Three patients in the group aged 12 to 17 years had mild dysphoria consisting of tearfulness and minimal agitation, which required no interventions. One patient in the group aged 2 to 5 years received midazolam for significant agitation. Six of the 60 patients had some but not unpleasant awareness of the fracture reduction. Fracture reductions were unsuccessful for 3 patients, all in the group aged 12 to 17 years. All 3 had unstable midshaft fractures of radius and ulna and underwent operative reduction and pinning. Parent satisfaction was high in all age groups.
LIMITATIONS
Our estimated ED 95 was not precise because of small sample size and limited dose range. We studied a small sample of healthy children in an inner-city ED who were undergoing forearm fracture reductions. We may not necessarily be able to generalize our ED 50 and ED 95 to other painful procedures and different populations. Although the adverse event profile in this study is encouraging, the small sample size limits our ability to claim safety. Most of the patients were pretreated with opioids, which may have affected the ED 50 , but it is a common practice to administer opioid pain medication for painful conditions such as fractures while the patient is awaiting diagnosis and treatment. Our sedation effectiveness criteria were not previously validated. Finally, the principal investigator's determination of the time of full recovery had potential for bias, but a standardized recovery assessment tool was used to minimize this possibility.
DISCUSSION
Many painful procedures necessary in the care of acutely injured children are brief. In our study, the median times to complete fracture reductions were 2.5 to 4 minutes, consistent with that in the study by Sharieff et al. 22 Our rapid administration of smaller intravenous ketamine doses achieved brief effective sedation for fracture reductions, with full recovery within 30, significantly faster than the 45 to 84 minutes reported in other studies that used larger, more slowly administered doses of ketamine. 5, 6, 23 Patients requiring additional doses of ketamine also had shorter total sedation time that ranged from 25 to 45 minutes (Table 2) . When additional ketamine is necessary to achieve or maintain effective sedation, rapid infusion of smaller doses enables rapid titration to the desired effect.
No patient in our study had a significant cardiopulmonary adverse event or unpleasant recall of the procedure. We have been using the rapid infusion technique before the start of the study and have noticed a similar safety profile. Confirmatory studies with large sample sizes are necessary to fully evaluate the safety of this approach. The frequencies of minor adverse events such as vomiting and recovery dysphoria were low, except for the higher frequency of emesis after discharge observed in the group aged 2 to 5 years.
In the group aged 2 to 5 years, 9 patients received a dose of 0.7 mg/kg but only 5 of them achieved effective sedation. Seven patients received 0.8 mg/kg or higher and all of them achieved effective sedation. Although the calculated ED 95 is 0.72 mg/kg, according to our data, 0.8 mg/kg is more reflective of ED 95 and consistently achieved effective sedation. Two patients in the group aged 6 to 11 years and 1 patient in the group aged 12 to 17 years received doses Figure. Sequence of patients in fracture groups aged 2 to 5, 6 to 11, and 12 to 17 years, showing first dose of ketamine (>), total amount of ketamine for procedure completion (Â), and Wisconsin Sedation Scale score at 1 minute (-). Patients received prespecified first dose of ketamine according to the response of the previous patient in the group. For the 20th patient, the first dose of ketamine was effective in the groups aged 2 to 5 and 6 to 11 years and was ineffective in group aged 12 to 17 years. Wisconsin Sedation Scale score 2 is assigned when a patient under sedation slowly arouses to consciousness with sustained painful stimulus. equivalent to or higher than ED 95 and had effective sedation. Further studies are needed to determine a more precise ED 95 . Forty of 60 patients received additional doses of ketamine. This is to be expected with the up-down method, in which the ED 50 is being estimated. In addition, some of the forearm fracture reductions were more difficult and required more prolonged sedation. Orthopedic residents in different years of training participated in the fracture reduction, which can affect the number of attempts and length of sedation. Additional doses of ketamine were also administered to approximately 30% of patients in other studies that used larger initial doses. 6, 23 Sedation providers may still choose to select the ED 95 as a starting dose, anticipating that additional ketamine may be necessary for some reduction attempts. When dealing with displaced fractures that might require multiple reduction attempts, providers can extend the length of sedation by using the rapid infusion technique to administer additional doses of ketamine, titrating to effect. Patients' responsiveness and depth of sedation are the key determinants of the need for and amount of additional doses of ketamine. The pharmacokinetic modeling of recovery from ketamine sedation by Dallimore et al 24 suggests that recovery is more rapid when repeated smaller doses are administered instead of a large initial dose that achieves the same length of effective sedation time.
We estimated that the minimum dose of ketamine infused during less than 5 seconds that is expected to provide 3 to 5 minutes of effective sedation for children undergoing fracture reduction would be 0.8 mg/kg for groups aged 2 to 5 years, 0.7 mg/kg for groups aged 6 to 11 years, and 0.8 mg/kg for groups aged 12 to 17 years. These ketamine doses are smaller than those used in most clinical studies in children 1, 3, 4, [6] [7] [8] 23 and are what is recommended in a widely accepted clinical practice guideline. 4 We believe that, similar to propofol and other intravenous anesthetic induction drugs, rapid infusion of smaller doses of ketamine achieves clinical effectiveness because it likely achieves a ketamine concentration at the site of action in the brain similar to that of larger doses more slowly infused, 9, 10 and rapid redistribution of this smaller dose of drug out of the brain leads to shorter recovery. Because most sedative drugs cause respiratory depression and hypotension when rapidly infused, this technique is undesirable for patients undergoing brief sedation in the ED. Ketamine, however, is associated with minimal cardiopulmonary depression. 14, [25] [26] [27] [28] [29] [30] [31] [32] [33] No widely accepted and validated criteria for effective sedation currently exist. 34, 35 To the best of our knowledge, this is the first study that has defined criteria for clinical effectiveness of sedation, which is one of the 6 objective measures for quality of sedation. 34 We created a simple tool to standardize a more uniform determination of clinically effective sedation (Table E2, available online at http://www.annemergmed.com). Our criteria were similar to those recently proposed by the Society for Pediatric Sedation. 34 These criteria focus on maximizing the patient's comfort and create optimal operative conditions while minimizing adverse events throughout the procedure. Our k statistic value of greater than 0.8 for consensus decisions and each grader indicates near perfect agreement between our expert video reviewers using these criteria. 21 Overall, 15 of the participants (20%) vomited either in the ED or after discharge. We observed, but do not have a clear explanation for, a higher frequency of vomiting in the group aged 2 to 5 years (35% either in the ED or after discharge) than previously reported in pediatric ketamine studies (18% to 25%). 3, 36, 37 During triage, we routinely offer and administer oral opioid analgesia to children likely to have fractures. More than 90% of patients in this study received opioids before procedural sedation in contrast with 30% to 40% reported in previous studies. 36, 37 Opioids are likely to increase the risk of emesis; a disproportionately higher frequency was observed in the group aged 2 to 5 years.
Our novel technique is significantly different from the current practice of administering ketamine at 1.5 to 2 mg/kg during 30 to 60 seconds. A rationale for slow administration of ketamine during 30 to 60 seconds is the concern for respiratory depression observed in early studies. In some of these studies, patients received higher doses of ketamine (!2 mg/kg), 5, 38 and in other studies there were anecdotal reports of respiratory depression without mention of the dose administered. 39, 40 In their metaanalysis, Green et al 14 concluded that intravenous doses of ketamine greater than or equal to 2.5 mg/kg or total doses greater than or equal to 5.0 mg/kg are independent predictors of airway and respiratory adverse events with ketamine sedation. We believe rapid administration of ketamine is safe at smaller doses. However, an assessment of airway and respiratory adverse events in a large cohort of patients is required to clarify safety of this technique. As with all procedural sedation techniques, providers should be prepared for unanticipated adverse events when using the rapid infusion, small-dose ketamine technique.
We conclude that rapid infusion of small doses of ketamine achieves effective brief sedation and rapid recovery; the adverse events frequency and severity appear to be comparable to those reported in previous studies. We estimated the ED 50 and ED 95 for our rapid infusion technique of ketamine in healthy children aged 2 to 17 years and undergoing brief forearm fracture reductions.
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